STOCK TITAN

Medicenna Thera (MDNAF) Stock News

MDNAF OTC

Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.

Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.

Rhea-AI Summary

Medicenna Therapeutics (MDNAF) reported a narrower fiscal second-quarter net loss while warning that additional financing is required to sustain operations. For the quarter ended September 30, 2026, net loss was $4.0 million, or $0.04 per share, versus $4.9 million, or $0.06 per share, a year earlier. Cash fell to $3.7 million from $5.7 million at June 30, 2026, and is insufficient for planned operations over the next twelve months.

MDNA11's Phase 1/2 ABILITY-1 trial completed enrollment of 152 patients. Among 20 evaluable biomarker-selected gastrointestinal cancer patients, the response rate was 40% and disease control rate was 80%; five of eight responses were confirmed. Bizaxofusp produced median survival of 13.7 months versus 6.2 months in an external control among high-dose, confirmed IDH-wildtype patients. Medicenna plans regulatory discussions for MDNA11 and is pursuing partnerships for bizaxofusp and MDNA209.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.25%
Tags
-
Rhea-AI Summary

Medicenna Therapeutics (MDNAF) reported longer median overall survival with bizaxofusp in a Phase 2b subgroup compared with matched external controls.

Among 19 patients with unresectable recurrent glioblastoma, confirmed IDH-wildtype tumors and doses of at least 180 micrograms, median survival was 13.7 versus 6.2 months (p=0.013). Twelve-month survival was 52.6% versus 15.6%; 24-month survival was 26.3% versus 6.7%. Median survival also favored bizaxofusp in the broader IDH-wildtype population and full per-protocol population. The retrospective, non-randomized comparison remains susceptible to residual confounding and requires randomized confirmation.

Medicenna proposes a hybrid Phase 3 trial using a single 240-microgram dose, approximately 200 randomized patients and an external control supplement. The FDA agreed that a randomized standard-of-care arm supplemented by eligibility-matched external controls was feasible.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
none
-
Rhea-AI Summary

Medicenna (MDNAF) presented Phase 1/2 ABILITY-1 data showing a 40% objective response rate in biomarker-selected gastrointestinal cancers resistant to approved therapies. Among 20 efficacy-evaluable patients treated with MDNA11 alone or with pembrolizumab, eight responded and 16 achieved disease control. Five of eight responses were confirmed; the response rate includes unconfirmed responses. Median response duration was not reached, with responses ongoing.

MDNA11 monotherapy produced regression in all eight measurable liver target lesions across four evaluable patients. In melanoma expansion cohorts, response rates were 30% with monotherapy in secondary checkpoint-inhibitor resistance and 38% with combination therapy in primary resistance. Combination therapy produced a confirmed 28.6% response rate in seven endometrial cancer patients. No dose-limiting toxicities occurred through 120 µg/kg; one Grade 4 cytokine release syndrome event resolved within four days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
none
Rhea-AI Summary

Medicenna Therapeutics (MDNAF) has completed enrollment of 152 patients in its global Phase 1/2 ABILITY-1 study of investigational cancer therapy MDNA11.

The study evaluates MDNA11 alone and in combination with Merck’s KEYTRUDA (pembrolizumab), with patients enrolled across Canada, the United States, Australia, Europe and South Korea. Updated study data will be presented at the Society for Immunotherapy of Cancer annual meeting on November 7, 2026. Medicenna will discuss the findings during a live expert webinar on November 10, from 9:00 to 10:00 a.m. EST, featuring management and physicians Hussein A. Tawbi and André Mansinho.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary

Medicenna Therapeutics (MDNAF) reported preclinical MDNA209 results showing longer survival in two aggressive mouse models of acute graft-versus-host disease. Long-acting MDNA209 improved symptoms, with median survival reaching 23.5 and 26 days, versus 7 days in each control group. Body weight recovery followed initial transplant-related loss.

MDNA209 blocked CD122, a receptor component involved in IL-2 and IL-15 immune signaling. In one human T-cell signaling assay, it was approximately 150 times more potent than Mikβ1 and 10 times more potent than a daclizumab biosimilar. Other laboratory findings included reduced immune-cell expansion and inflammatory signaling; four days of treatment did not reduce human regulatory T-cell viability. The findings were presented on October 23, 2026, in Paris. Medicenna is pursuing potential partnership opportunities for MDNA209.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
-
Rhea-AI Summary

Medicenna Therapeutics (MDNAF) will present new preclinical data on MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference.

Dr. Minh D. To will deliver the presentation on October 23, 2026, from 4:30–5:00 PM CEST in Paris, France. MDNA209 is an engineered protein designed to block CD122, a component of the receptors for the immune signaling molecules IL-2 and IL-15, and inhibit signaling by both molecules. The company says the presentation will further characterize MDNA209’s potency and approach to targeting these pathways.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
none
Rhea-AI Summary

Medicenna Therapeutics (MDNAF) announced that topline MDNA11 study data will be presented orally at SITC on November 7, 2026.

The Phase 1/2 ABILITY-1 trial evaluates MDNA11 in expansion cohorts of patients with advanced and metastatic gastrointestinal, endometrial and melanoma cancers. Abstract 517 was selected among the meeting's Top 150 Abstracts. Its title describes clinical activity in gastrointestinal malignancies selected using biological markers, with MDNA11 alone and with pembrolizumab, including disease resistant to immune checkpoint inhibitors.

The presentation is scheduled for 4:30–4:45 p.m. MST in Oral Session 3 at the Phoenix Convention Center, Room 301D, in Phoenix, Arizona.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
-
Rhea-AI Summary

Medicenna Therapeutics (MDNAF) shareholders authorized a potential share consolidation at the annual general and special meeting held October 1, 2026. The board may choose a ratio of one post-consolidation share for every 2 to 20 pre-consolidation shares, or decide not to proceed. Any implementation requires regulatory approvals; the ratio and effective date would be announced once the board decides to proceed.

The company said consolidation could support minimum bid-price compliance for a potential major U.S. exchange listing and attract investors with minimum share-price requirements. A listing would still require satisfaction of all applicable requirements and exchange approval. Shareholders also elected all four director nominees, each with more than 97% support, and reappointed MNP as auditor. 31.82% of outstanding common shares were represented at the meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
Rhea-AI Summary

Medicenna (MDNAF) will present an analysis of bizaxofusp survival outcomes in recurrent glioblastoma at SNO 2026 on November 13.

The analysis concerns unresectable, IDH-wildtype recurrent glioblastoma in the intended Phase 3 population and uses a propensity score-weighted external control arm. Nicholas Butowski is scheduled to give the oral presentation at 10:36 a.m. ET in Philadelphia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.89%
Tags
none
Rhea-AI Summary

Medicenna Therapeutics (MDNAF) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026. President and CEO Dr. Fahar Merchant is scheduled to present on September 16, 2026, from 12:00 PM to 12:30 PM EST at the Lotte New York Palace Hotel.

The presentation will be held in the Kennedy II room on the 4th floor and will be webcast live, with replay access available for 90 days via the investor relations Events & Presentations section of Medicenna’s website. Investors can also request one-on-one meetings with Dr. Merchant through conference registration or their H.C. Wainwright representative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
none

FAQ

What is the current stock price of Medicenna Thera (MDNAF)?

Medicenna Thera (MDNAF) last closed at $0.1250.

What is the market cap of Medicenna Thera (MDNAF)?

The market cap of Medicenna Thera (MDNAF) is approximately $11.5M.